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Cummings BP, Digitale EK, Stanhope KL, Graham JL, Baskin
DG, Reed BJ, Sweet IR, Griffen SC, Havel PJ. Development and
characterization of a novel rat model of type 2 diabetes mellitus: the
UC Davis type 2 diabetes mellitus UCD-T2DM rat. Am J Physiol
Regul Integr Comp Physiol 295: R1782–R1793, 2008. First published
October 1, 2008; doi:10.1152/ajpregu.90635.2008.—The prevalence
of type 2 diabetes (T2DM) is increasing, creating a need for T2DM
animal models for the study of disease pathogenesis, prevention, and
treatment. The purpose of this project was to develop a rat model of
T2DM that more closely models the pathophysiology of T2DM in
humans. The model was created by crossing obese Sprague-Dawley
rats with insulin resistance resulting from polygenic adult-onset obe-
sity with Zucker diabetic fatty-lean rats that have a defect in pancre-
atic -cell function but normal leptin signaling. We have character-
ized the model with respect to diabetes incidence; age of onset;
longitudinal measurements of glucose, insulin, and lipids; and glucose
tolerance. Longitudinal fasting glucose and insulin data demonstrated
progressive hyperglycemia (with fasting and fed glucose concentra-
tions 250 and 450 mg/dl, respectively) after onset along with
hyperinsulinemia resulting from insulin resistance at onset followed
by a progressive decline in circulating insulin concentrations, indic-
ative of -cell decompensation. The incidence of diabetes in male and
female rats was 92 and 43%, respectively, with an average age of
onset of 6 mo in males and 9.5 mo in females. Results from
intravenous glucose tolerance tests, pancreas immunohistochemistry,
and islet insulin content further support a role for -cell dysfunction
in the pathophysiology of T2DM in this model. Diabetic animals also
exhibit glycosuria, polyuria, and hyperphagia. Thus diabetes in the
UC Davis-T2DM rat is more similar to clinical T2DM in humans than
in other existing rat models and provides a useful model for future
studies of the pathophysiology, treatment, and prevention of T2DM.
diabetic rodent model; hyperglycemia; insulin; -cell
TYPE 2 DIABETES MELLITUS (T2DM) is a devastating metabolic
disease presently affecting at least 16 million people in the
United States alone (33, 49). The prevalence of T2DM is also
increasing in children and adolescents (42). With the increas-
ing incidence of T2DM, the identification of preventative
measures has become crucial, necessitating the development of
effective preclinical models for studying approaches for both
diabetes prevention and treatment.
The most commonly used rodent models of T2DM include
the Zucker diabetic fatty (ZDF) rat, the Otsuka Long Evans
Tokushima fatty (OLETF) rat, and the db/db mouse, all of
which exhibit obesity-associated insulin resistance and im-
paired -cell function, resulting in diabetes (5, 25, 38). While
these animal models have contributed substantially to under-
standing the pathophysiology and treatment of T2DM and its
complications, the basic mechanisms underlying the pathogen-
esis of diabetes in these models do not correspond with what
occurs in most human patients with T2DM. These differences
in etiology are likely to hinder effective translational research.
Obesity and insulin resistance in most animal models of
T2DM result from monogenic mutations that are rare in human
and animal populations and present multiple problems in terms
of applying these models to clinical T2DM. For example,
mutations in the leptin receptor gene result in obesity and
insulin resistance in both the ZDF rat and the db/db mouse (17,
37). Obesity in OLETF rats is thought to result in part from a
single mutation in the gene encoding the CCK-A receptor (12,
13); however, these animals also exhibit other poorly charac-
terized X-linked genetic defects (25). Relying on animal mod-
els with rare monogenic mutations for diabetes development is
likely to produce confounding effects in studies utilizing these
models. For example, leptin receptors expressed in pancreatic
-cells (27) have been implicated in the regulation of -cell
function (46, 47, 56). The absence of leptin signaling in the
ZDF rat and the db/db mouse can therefore result in effects on
-cell function that are atypical of the human disease. In
addition, leptin opposes insulin resistance, in part, via activa-
tion of AMP kinase causing a reduction in lipid deposition in
insulin-sensitive tissues (20). Thus the lack of effective leptin
signaling in ZDF rats and db/db mice promotes the develop-
ment of diabetes involving mechanisms that do not commonly
occur in clinical diabetes in humans. Furthermore, defective
leptin signaling results in severe obesity and insulin resis-
tance at a very early age. ZDF rats are obese at weaning (36)
and hyperglycemic by 7–10 wk of age (37), whereas human
obesity and insulin resistance resulting in T2DM are typi-
cally less severe and more often appear in adolescence and
adulthood (18). This characteristic of early diabetes onset
limits the use of currently available rodent models in dia-
betes prevention studies.
Leptin deficiency and leptin signaling defects also result in
complete infertility in females (58); however, infertility is not
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a typical characteristic of diabetes in humans. This lack of
fertility also makes the propagation of ZDF rats difficult, as
only heterozygous animals can be bred. Finally, for reasons
that are not well understood, female rodents are generally
resistant to the development of diabetes (24) or become dia-
betic only when fed high-fat, high-sugar diets (34). In contrast,
in many population groups, women develop diabetes more
frequently than men (28). These shortcomings of currently
available models highlight the need for new rodent models of
T2DM.
Because the development of T2DM in humans requires both
peripheral insulin resistance and inadequate -cell compensation,
we sought to develop a new rat model demonstrating polygenic
adult-onset obesity and diabetes development in both sexes with
preserved leptin signaling and fertility. We hypothesized that
these characteristics would be present in offspring produced by
crossing obese insulin-resistant Sprague-Dawley (OSD) rats with
ZDF-lean rats. The breeding strategy was to cross these two
lines of nondiabetic rats, each of which has only one of the
primary defects associated with T2DM, and to then use selec-
tive breeding to enrich for diabetes in subsequent generations.
One founder line consisted of OSD rats that exhibit polygenic,
adult-onset obesity and insulin resistance on a standard labo-
ratory rat chow diet but do not develop diabetes due to robust
-cell compensation (52). The second founder line, ZDF-lean
rats, do not possess the leptin receptor mutation but have a
defect in pancreatic -cell insulin production (15) that results
in diabetes only in the setting of insulin resistance. These
studies demonstrate that this breeding strategy successfully
produced diabetes in both male and female animals with
animals exhibiting adult-onset obesity, insulin resistance, im-
paired glucose tolerance, and eventual -cell decompensation.
This model provides several advantages over currently avail-
able models including obesity of polygenic rather than mono-
genic origin, a later age of onset, preserved fertility, and
development of diabetes in both sexes.
METHODS
Animals. Rats were housed and bred in the animal facility in the
Department of Nutrition at the University of California, Davis, and
maintained on a 12-h light-dark cycle. The experimental protocols
were approved by the University of California Davis Institutional
Animal Care and Use Committee.
Obese Sprague-Dawley (OSD) rats were originally obtained from
Charles River Laboratories (Wilmington, MA). These animals gain
weight more rapidly than Sprague-Dawley rats purchased from a
different vendor, Harlan Laboratories (Indianapolis, IN; Ref. 51). The
OSD rats exhibit adult-onset obesity and are hyperphagic and more
metabolically efficient than normal weight animals (35, 39, 51). This
obese phenotype appears polygenic in origin (31), with the OSD
littermates exhibiting a wide continuum of body weights, rather than
distinct “obese” and “lean” phenotypes as observed in monogenic
models of obesity. Compared with lean Sprague-Dawley rats (LSD),
OSD rats exhibit an early increase of visceral adipose mass and low
circulating adiponectin concentrations (at 1 mo of age); increased
fasting insulin concentrations and hepatic triglyceride (TG) deposition
(at 3 mo); increased plasma nonesterified fatty acids and muscle TG
content (at 6 mo); and progressive insulin resistance over their life
span. However, even at 20 mo of age, they have only minimally
elevated fasting glucose (112 mg/dl vs. 97 mg/dl in OSD and LSD
rats, respectively; P  0.02) and thus do not develop diabetes (52). In
this regard, OSD rats are similar to most obese humans who develop
insulin resistance but have robust -cell function, which allows for
sufficient compensatory insulin secretion and hyperinsulinemia with-
out hyperglycemia.
ZDF-lean founder animals were purchased from Charles River
Laboratories and genotyped via the tail-snip method to confirm that all
founder animals were homozygous wild-type (/) at the leptin
receptor locus (40). ZDF-lean rats have the autosomal recessive -cell
defect (15) but have functional leptin receptors and thus do not
develop obesity or insulin resistance and are fertile. -Cell function,
although impaired, is sufficient to maintain normoglycemia in the
absence of obesity-induced insulin resistance.
Breeding strategy. ZDF-lean male rats were mated with OSD
females to produce the F1 generation, which was heterozygous for the
autosomal recessive -cell defect; thus animals did not develop
diabetes. The heaviest F1 animals were bred to siblings to produce the
F2 generation. Body weight and nonfasting blood glucose were
monitored every 2 wk with a glucose meter (One-Touch Ultra;
LifeScan, Milpitas, CA) in the F2 and subsequent generations. Dia-
betes onset was defined as a nonfasting blood glucose concentration
200 mg/dl obtained on two consecutive measurements, and the age
of onset was defined as the age at which hyperglycemia was first
detected. For F3 and subsequent generations, obese and hyperglyce-
mic animals were bred to siblings with the goal of maintaining the
obese phenotype and selecting for individuals homozygous for the
autosomal recessive -cell defect. Starting with the F7 generation, all
animals were produced from matings in which both parents were
either currently diabetic or subsequently developed diabetes, meaning
that all animals are considered homozygous for the -cell defect.
Characterization of diabetes incidence rates. Diabetes incidence
and age of onset were systematically characterized in the F7 genera-
tion, with all animals in this generation undergoing body weight and
nonfasted blood glucose monitoring until diabetes onset was reached.
This was the first generation chosen to determine diabetes incidence
since this was the first generation in which all animals were homozy-
gous for the -cell defect, and therefore, all animals in this generation
and onward had the genetic propensity to develop diabetes. Animals
were weaned at 21 days, housed in polycarbonate cages, and fed a
standard commercial diet (no. 5008; Ralston Purina, Belmont, CA)
and deionized water ad libitum.
Eighteen-month longitudinal study. Body weight, energy intake,
and plasma lipids and hormones were determined before and after
diabetes onset in a cohort of 16 male rats from the F9 and F10
generations. Rats were individually housed on hanging wire cages and
provided ground chow (no. 5012; Ralston Purina; supplemented with
safflower oil to 24% of energy as fat) in spill-resistant jars for accurate
food intake measurements. Food intake and body weight were mea-
sured three times a week, and nonfasted blood glucose concentrations
were monitored weekly at 1500. Diabetes onset was defined as
described above. Fasted blood samples were collected once a month
after an overnight (12 h) fast in EDTA-treated tubes and were
analyzed for glucose, insulin, glucagon, free fatty acids (FFA), TG,
leptin, adiponectin, and ghrelin.
Intravenous glucose tolerance testing. Glucose tolerance tests were
performed on unanesthetized male F12 and F13 animals before onset
(at 3 mo of age), 3 wk after diabetes onset, and 3 mo after diabetes
onset. Animals were fasted overnight, and a 27-gauge butterfly cath-
eter was placed in the saphenous vein for infusion of a bolus dose of
500 mg/kg body wt of a 50% dextrose solution. Blood samples were
collected from the tail at 0, 2.5, 5, 10, 20, 30, 45, 60, 90, 120, and 180
min after glucose administration.
Islet immunohistochemistry. Pancreas samples were obtained from
four groups of male rats: 4-mo-old LSD rats obtained from Harlan as
a control; 4-mo-old nondiabetic University of California, Davis, type
2 diabetes mellitus (UCD-T2DM) rats; and UCD-T2DM rats 3 wk and
3 mo after diabetes onset. Briefly, pancreas samples were dissected
under pentobarbital anesthesia and placed in 4% paraformaldehyde at
4°C and imbedded in paraffin. Sections (6-M thick) were treated
with 0.3% hydrogen peroxide for 30 min, followed by 5% normal goat
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serum in PBS, and then immunostained following a standard protocol
(57). Antibodies used were 1) monoclonal anti-insulin (Sigma I-2018)
at 6 g/ml; and 2) monoclonal anti-glucagon (Sigma G-2654) at 10
g/ml, 4°C overnight. Detection of insulin and glucagon was by the
ABC Elite kit (Vectastain PK-6100, Vector Laboratories) and diami-
nobenzidine-H2O2 (Vector SK-4100), and counterstained in hematox-
ylin. For controls, normal mouse IgG was substituted (Jackson Im-
munoReserach 015-000-002) at 10 g/ml. Controls showed no stain-
ing of islet cells. Original images of immunostained islets were
captured as 16-bit RGB JPEG files. Each full original JPEG file was
globally processed with the Auto Levels function of Adobe Photoshop
to adjust color balance and contrast (no other manipulations were
performed on the original image files).
Islet isolation, insulin content, and islet volume determination.
Islets were isolated from age-matched (3 mo) pre- or postdiabetic
male UCD-T2DM rats and LSD (Harlan, Livermore, CA) rats. Rats
were anesthetized by intraperitoneal injection of sodium pentobarbital
(150 mg/kg). Each isolation involved obtaining islets from three rat
pancreases that were then pooled. Islets were prepared and purified as
described previously (54) and then cultured for 18 h at 37°C in RPMI
media 1640 supplemented with 10% heat-inactivated FBS (Invitro-
gen) before the experiments. Islets were examined under a TE-2000
Eclipse microscope (Nikon), and the number of islets less than or
greater than 250 m (as assessed using a calibrated reticle in the
eyepiece) were counted and placed into separate dishes. Images of
islets from each group were taken at 4 magnification using a Nikon
Coolpix camera mounted into the eyepiece of the microscope. Insulin
content per islet was determined by placing islets from each group
into wells of 24-well plates (5 islets into each of 3 wells) containing
0.2 ml of culture media, insulin was extracted by the addition of 1 ml
of a mixture of ethanol and hydrochloric acid (2% v/v HCl to 95%
ethanol), and the supernatant was collected after 60 min. Insulin was
measured by ELISA (Mercodia, Uppsala, Sweden). Islet volume was
estimated as follows. Images of at least 50 islets from each preparation
were sized using ImageJ (National Institutes of Health, Bethesda,
MD) by manually tracing around the perimeter of each islet using the
virtual drawing tool, and the area within the region enclosed by the
trace was calculated by the program. The diameter was calculated
from the area as if the area was a circle according to the equation: d
2 area/. The volume of the idealized spherical islet was then
calculated as 4/3  (d/2)3, and total islet volume for a preparation was
the sum of the volumes of all the islets isolated.
Urinary glucose and albumin. Male rats from the F12 and F13
generations were studied to assess urinary glucose and albumin
excretion. Twelve-hour urine samples were collected in sodium azide
treated flasks and assayed for glucose and albumin. Urinary albumin
excretion was measured using the Albumin Blue 580 fluorescence
assay method described previously (26).
Visceral adiposity and liver and muscle TG content. Mesenteric
adipose depots and liver and gastrocnemius muscle samples were
obtained from four groups of 6-mo-old animals: LSD (Harlan) rats,
OSD rats (Charles River), recently diabetic male F4 and F5, and
weight-matched nondiabetic UCD-T2DM rats. The mesenteric adi-
pose depot was dissected and weighed. Liver and muscle tissues were
immediately placed in liquid nitrogen and stored at80°C. Tissue TG
was measured using the Folch method (9) for lipid extraction followed
by spectrophotmetric measurement of TG content (Thermo Electron,
Louisville, CO).
Assays. Plasma and urine glucose were measured using an enzy-
matic colorimetric assay for glucose (Thermo DMA). Insulin, leptin,
glucagon, and adiponectin were measured with rodent/rat specific
RIAs (Linco/Millipore, St. Charles, MO). Ghrelin was measured by
RIA (rat-mouse ghrelin; Phoenix Pharmaceuticals, Burlingame, CA),
and FFA and TG were measured with enzymatic colorimetric assays
(NEFA Microtiter C kit, L-type TG H kit; Wako Chemicals, Rich-
mond, VA).
Statistics and data analysis. Data are presented as means 	 SE.
Statistical analyses were performed using GraphPad Prism 4.00 for
Windows (GraphPad Software, San Diego, CA). Longitudinal data
were compared by one-way repeated measures ANOVA followed by
post hoc analysis with Bonferroni’s multiple comparison test. Inci-
dence data divided into 2-mo body wt classes were analyzed by
log-rank testing of Kaplan-Meier survival curves. Body weight and
energy intake data in LSD compared with UCD-T2DM rats were
compared by two-way repeated measures ANOVA followed by post
hoc analysis with Bonferroni’s multiple comparison test. Age of
onset, mesenteric adipose weights, tissue TG and islet yield, size, and
insulin content/islet volume results were analyzed by one-way
ANOVA followed by post hoc analysis with Bonferroni’s multiple
comparison test. For the intravenous glucose tolerance test (IVGTT)
data, the area under the curve (AUC) was calculated and compared by
Student’s t-test. Differences were considered significant at P 
 0.05.
Since the age of diabetes onset is not uniform, longitudinal data were
analyzed by normalizing to the time of diabetes onset.
RESULTS
Both male and female UCD-T2DM rats develop diabetes. As
previously discussed, the F7 generation is the generation for
which a complete data set for age of onset and diabetes
incidence is available for both male and female animals. Due to
space limitations for housing animals, only male rats in sub-
sequent generations have been monitored until diabetes onset.
The incidence of diabetes in male and female rats in the F7
generation was 91.9% (102/111) and 42.6% (40/94) respec-
tively, with the average age of onset being 183 	 10 days in
males and 286 	 17 days in females (Table 1; P 
0.0001,
males vs. females).
Kaplan-Meier survival analysis was performed to examine
diabetes incidence in F7 female and F7 through F13 male rats.
Division of animals into groups based on body weight at 2 mo
of age demonstrates that early body weight greatly influences
incidence and age of onset (Fig. 1, A and B). Male animals with
a 2-mo body wt 400 g have an incidence of 99.1% with an
average age of onset of 95 	 5 days, whereas male rats
weighing
350 g at 2 mo of age have an incidence of 86% and
age of onset of 243 	 13 days (P 
 0.0001). The effect of
Table 1. Incidence and age of onset in male and female
UCD-T2DM rats
Gender/Generation Incidence, % Age of Onset, day n
Males
F7 91.9 183	10 111
F7–F13, 
350 g 86.0 243	13 93
F7–F13, 350–400 g 96.4 162	8* 112
F7–F13, 400 g 99.1 95	5* 107
Females
F7 42.6 286	17† 94
F7, 
240 g 21.1 375	19 57
F7, 240–270 g 59.1 326	22 22
F7, 270 g 100 179	17* 15
Values are means 	 SE. UCD-T2DM, University of California, Davis, type
2 diabetes mellitus. *P 
 0.0001, by Student’s t-test, compared with lowest
weight class. †P 
 0.0001, by Student’s t-test, compared with male F7
animals.
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increased 2-mo body wt on incidence rate is even more
pronounced in females. Female rats weighing 
240 g at 2 mo
have an incidence of 21% and an average age of onset of 375	
19 days, whereas 100% of females weighing 270 g at 2 mo
of age develop diabetes with diabetes onset at 179 	 17 days
(P 
 0.0001; Table 1).
Progressive hyperglycemia and inadequate -cell compen-
sation. The average age of onset in the cohort of male animals
from the F9 and F10 generations that were monitored for 18
mo was 212 	 16 days. Longitudinal measurements of plasma
glucose and insulin concentrations centered at the time of
diabetes onset demonstrate increasing insulin resistance before
diabetes onset followed by inadequate pancreatic -cell com-
pensation at the time of onset and -cell decompensation
within 2–3 mo after onset (Fig. 2). Nonfasting hyperglycemia
is present at onset (246 	 12 mg/dl) and increases to 488	 18
mg/dl by 3 mo after onset (P 
 0.001; Fig. 2). Fasting plasma
glucose averaged 114 	 2 mg/dl at onset and increased to
277 	 22 mg/dl at 3 mo after onset (P 
 0.001), suggesting
that the hyperinsulinemia present at onset maintains lower
glucose concentrations in the fasted state. Three months before
onset fasting plasma insulin concentrations were 1.8 	 0.3
ng/ml and increased to peak insulin levels of 3.4 	 0.2 ng/ml
at the time of diabetes onset (P 
 0.001), corresponding with
the increase in nonfasting glucose during the same period.
Over the 3 mo after the development of hyperglycemia, there
is a marked and progressive decline of fasting insulin levels
(0.9	 0.2 ng/ml at 3 mo after onset; P
0.001, compared with
value at onset) despite the presence of pronounced fasting and
nonfasting hyperglycemia.
Impaired glucose tolerance and loss of insulin secretion
during IVGTT. Plasma glucose concentrations during IVGTT
indicate impaired glucose clearance before diabetes onset com-
pared with previous data from IVGTTs performed in LSD rats
of similar age (8) and a marked deterioration of glucose
homeostasis as diabetes progresses. At 3 wk after diabetes
onset, the animals exhibit similar initial glucose excursions to
prediabetic UCD-T2DM animals, but insulin excursions are
significantly lower in recently diabetic compared with predia-
betic animals (IVGTT insulin AUC: nondiabetic  527 	 58
and recently diabetic 216	 44 ng/ml 180 min; P
 0.05)
in response to glucose administration. Three months after
diabetes onset, there is a large increase in the glucose AUC,
compared with prediabetic animals, (IVGTT glucose AUC:
nondiabetic  18,611 	 2,191, recently diabetic  17,706 	
1,727, and diabetic for 3 mo  30,528 	 5,835 mg/dl  180
min; P
 0.001) with plasma glucose concentrations remaining
markedly elevated even 3 h after glucose administration. Sim-
ilar to recently diabetic animals, circulating insulin does not
increase in the 3-mo diabetic animals, remaining low despite
marked hyperglycemia (Fig. 3, A and B). The insulin AUC is
decreased by 88% compared with prediabetic animals (IVGTT
insulin AUC: 3-mo diabetic  64 	 9 ng/ml  180 min, P 

0.005).
Islet immunostaining and insulin secretion. Immunostaining
for insulin and glucagon was performed on pancreas sections
from selected animals from each group of animals that under-
went IVGTT to examine islet morphology and to determine
whether the failure to increase circulating insulin levels in
diabetic animals in response to glucose administration was due
to a reduction of insulin production. Figure 4 presents low
magnification images of pancreas sections. These images sug-
gest a progressive decrease of islet insulin staining with dia-
Fig. 2. Longitudinal nonfasted blood glucose and fasting plasma glucose and
insulin concentrations before and after diabetes onset. Values are means	 SE.
One-way repeated measures ANOVA, *P 
0.001 by Bonferroni’s posttest
compared with value at onset (n  16, n  14 4 mo after onset).
Fig. 1. Kaplan-Meier analysis of diabetes incidence in University of Califor-
nia, Davis, type 2 diabetes mellitus (UCD-T2DM) rats with animals catego-
rized by body weight at 2 mo of age in male F7-F13 generations (A) and the
female F7 generation (B). ***P 
 0.0001 by log rank test compared with
highest body weight class.
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betes progression. When compared with age-matched LSD
controls (Harlan; Fig. 5, A and B), nondiabetic UCD-T2DM rat
islets (Fig. 5, B and C) appear larger (likely hypertrophied).
Immuostaining for insulin and glucagon suggests dispersion of
- and -cells within these enlarged islets. Pancreas samples
from 4-mo-old prediabetic UCD-T2DM animals appear to
stain similarly for insulin and glucagon compared with animals
with diabetes of 1-mo duration (data not shown). Figure 5, E
and F, demonstrates the typical pathological islet morphology
in animals with diabetes of 3-mo duration. These animals
exhibit visibly reduced insulin and glucagon staining with
widely dispersed - and -cells and marked disruptions in islet
morphology.
To further study the characteristics of islets in the UCD-
T2DM rats, islets were isolated from these rats before and after
diabetes onset and their yield, size, volume and insulin content
were determined. Animals were age and weight matched (11
wk and 440 	 9 vs. 12 wk and 459 	 13 g for the pre- and
postdiabetic animals, respectively). Diabetic rats had been
diabetic for 3.5 wk. The control rats were LSD with an
average age of 10 wk and an average body weight of 303 	
8 g. Images of the isolated islets illustrate the increase in size
and disruption of islet architecture in both pre- and postdiabetic
rats (Fig. 6). To quantify the increase in size, islets were
isolated from the three rat types, and the yields of islets that
were below and above 250 m, the maximal size measured in
LSD rats, were determined (Fig. 7A). Approximately 55% of
islets isolated from both pre- and postdiabetic UCD-T2DM rats
were similar in size to those obtained from LSD rats. However,
45% of the islets were larger than the largest islets isolated
from LSD rats. The total number of islets isolated from pre-
and postdiabetic UCD-T2DM rats was 70% lower than LSD
controls (P 
 0.001). However, as an estimate of islet “mass,”
total islet volume was increased significantly in the UCD-
T2DM rats relative to the LSD rats (P 
 0.05; Fig. 7B). A
similar trend was seen with islet area (data not shown). The
actual areas and volumes may be an overestimate since islets
that are not spherical will lay down in such a way as to expose
the largest area. However, the method that measures islet
“mass” increases in UCD-T2DM rats appears to be model
independent. Importantly, islet yields were not reduced in
diabetic rats compared with prediabetic rats. Notably, like islet
volume, the insulin content in the prediabetic UCD-T2DM rats
was more than fivefold higher than in islets from LSD rats
(P 
0.001), and the insulin content per unit islet volume was
greater in prediabetic compared with LSD rats (P 
0.001; Fig.
7C). Islet insulin content was dramatically decreased in the
islets from diabetic UCD-T2DM rats (P 
 0.001). Thus it
appears that islet size and total volume are elevated in UCD-
T2DM rat islets, but the transition from the prediabetic state to
nonfasting hyperglycemia is associated with a marked decrease
of insulin content, rather than a decrease of islet volume.
Other features of T2DM. UCD-T2DM rats exhibit adult-
onset obesity and hyperphagia before developing diabetes,
when compared with LSD rats, followed by a progressive
increase in energy intake and slow loss of body weight after
diabetes onset. Table 2 compares monthly body weight and
energy intake by age in male UCD-T2DM rats with LSD rats.
Female UCD-T2DM rats reach an adult body weight of 411 	
7 g by 9 mo of age. Figure 8, A and B, shows body weight and
energy intake before and after diabetes onset in male UCD-
T2DM rats. One month before diabetes onset rats attain a body
weight of 619 	 16 g and consume 101 	 4 kcal/day. After
diabetes onset, there is a progressive increase in energy intake,
with animals consuming 148 	 8 kcal/day by 2 mo after onset
(P 
 0.001), indicative of hyperphagia observed in untreated
diabetes after -cell function has markedly declined. However,
this increase in energy intake is not sufficient to compensate for
the progressive impairment in glucose utilization, resulting in
decreased body weight with animals losing 5	 1 and 11	 1%
of peak body weight at 1 and 2 mo after onset, respectively
(n 15). Male rats studied during the F12 and F13 generations
exhibited polyuria, glucosuria, and albuminuria after onset
(Table 3).
Plasma lipids, visceral adiposity and tissue TG content.
Before diabetes onset, circulating FFA concentrations remain
stable at 0.76 	 0.04 meq/l (value at 1 mo before onset). In
contrast, plasma TGs progressively increase from 144 	 22
mg/dl at 4 mo before onset to 193 	 19 mg/dl at 1 mo before
onset (P 
 0.01; n  12). Correspondingly, recently diabetic
UCD-T2DM animals tend to have elevated mesenteric adipose
weights and liver and muscle TG content compared with
weight-matched nondiabetic UCD-T2DM animals. Liver and
Fig. 3. Plasma glucose (A) and plasma insulin (B) excursions in response to
intravenous glucose administration (500 mg/kg body wt and 50% dextrose
solution) in nondiabetic, 3-wk diabetic, and 3-mo diabetic UCD-T2DM rats
after an overnight fast. Values are means 	 SE. Two-way repeated measures
ANOVA, *P 
0.01 and **P 
0.001 by Bonferroni’s posttest compared with
the nondiabetic group (n  7 per group).
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muscle TG contents are significantly elevated (P 
 0.01) in
recently diabetic UCD-T2DM animals when compared with
age-matched LSD and OSD rats. Liver TG is also elevated in
prediabetic UCD-T2DM rats compared with LSD controls
(P 
 0.05). Similar to OSD rats, mesenteric adipose weights
are elevated in both prediabetic and diabetic UCD-T2DM rats
compared with LSD controls (P 
 0.05; Table 4). Circulating
TGs decline from 223 	 25 mg/dl at onset to 132 	 18 mg/dl
2 mo after onset, suggesting a decrease in lipid availability in
response to negative energy balance. Accordingly, plasma FFA
increase to 0.89 	 0.04 meq/l at 2 mo after onset (P 
 0.05),
which is likely the result of decreased inhibition of lipolysis by
insulin.
Longitudinal hormone measurements. Fasting plasma leptin
concentrations peaked at 11.6 	 0.6 ng/ml at the time of
diabetes onset and fell to 3.8 	 0.6 ng/ml at 3 mo after onset
(P
 0.001; Fig. 9A). Plasma adiponectin before diabetes onset
was 5.2 	 0.4 g/ml (1 mo before onset) and decreased to
3.9 	 0.3 g/ml by 1 mo after onset (P 
 0.01; Fig. 9B).
Fasting plasma glucagon remained stable at 45 	 2 pg/ml
before onset (value taken 1 mo before onset) and increased to
58 	 5 pg/ml by 4 mo after onset (P 
0.05; Fig. 9C).
Circulating ghrelin concentrations were elevated by 4 mo after
diabetes onset compared with values at onset (2,657 	 382 vs.
1,913	 200 pg/ml; P
0.05; Fig. 9D), corresponding with the
time of peak hyperphagia.
DISCUSSION
By crossing an obese, insulin resistant Sprague-Dawley rat
strain with ZDF-lean rats, we have generated a new rat model
of T2DM with diabetes occurring in both sexes and with
preserved leptin signaling and fertility. Preservation of leptin
signaling was ensured by initial genotyping of ZDF-lean
founder animals and was confirmed by demonstrating retained
fertility in subsequent generations and by measurements of
circulating leptin showing only modest increases of leptin
compared with Zucker fatty (fa/fa) and ZDF rats. Fasting leptin
concentrations peaked at 11.6 	 0.6 ng/ml at the time of
diabetes onset in the UCD-T2DM rats, whereas leptin concen-
trations in ZDF rats are reported to be20 ng/ml (11) and50
ng/ml in Zucker Fatty rats (29). Importantly, leptin concentra-
tions in prediabetic animals are comparable with those in OSD
rats from Charles River (29) and are appropriate for their
degree of adiposity. By the F7 generation, all animals are
considered to be homozygous for the -cell defect since they
are the offspring of diabetic parents. Thus all animals in this
and subsequent generations have the genetic propensity to
develop T2DM. Categorizing animals into groups based on
body weight at 2 mo of age demonstrates that age of onset and
incidence rate are highly influenced by early body weight.
These data are consistent with clinical observations that obesity
and insulin resistance lead to an earlier age of diabetes onset.
Fig. 4. Representative 20 magnification images of
anti-insulin immunohistochemical analysis of forma-
lin-fixed pancreas sections from male lean Sprague-
Dawley control rat (LSD) at 4 mo of age (A), nondia-
betic UCD-T2DM rat at 4 mo of age (B), 1-mo diabetic
UCD-T2DM rat at 3 mo of age (C), and 3-mo diabetic
UCD-T2DM rat at 6 mo of age (D).
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Multiple epidemiologic studies (2, 45) report an increased risk
for T2DM and an earlier age of onset in people with an
increased body mass index in youth and early adulthood. These
results also provide a useful tool for planning studies in that
animals can be selected based on 2-mo body wt to achieve a
high or low incidence rate and an early or later age of diabetes
onset.
The UCD-T2DM model provides several advantages over
currently available diabetic animal models. First, the patho-
physiolology of T2DM in these animals is more similar to that
observed in clinical human and animal cases than other cur-
rently available models with monogenic mutations, such as
those affecting leptin signaling that are extremely rare in
humans and that also result in infertility and very early diabetes
onset. In addition, elevated circulating TG, increased visceral
adiposity, and ectopic lipid deposition are believed to play
important roles in lipotoxicity and the pathogenesis of T2DM
in humans (55); however, the lack of leptin signaling in many
rodent models of the disease confounds results due to the
absence of AMP kinase-mediated, anti-lipotoxic actions of
leptin (20). The elevation of circulating TGs observed at onset
in UCD-T2DM rats (223	 25 mg/dl) is modest compared with
the extreme hypertriglyceridemia (plasma TG 1,000 mg/dl)
observed in ZDF rats at diabetes onset (30). Thus the predia-
Fig. 5. Representative immunohistochemical analysis of pancreas sections from male LSD controls and UCD-T2DM rats at various stages of diabetes. All
sections are at 100 magnification. Anti-insulin immunohistochemistry staining for the following: A: LSD control at 4 mo of age; C: nondiabetic UCD-T2DM
rat at 4 mo of age; and E: 3-mo diabetic UCD-T2DM rat at 6 mo of age. Anti-glucagon immunohistochemistry staining for the following: B: LSD control at
4 mo of age; D: nondiabetic UCD-T2DM rat at 4 mo of age; and F: 3-mo diabetic UCD-T2DM rat at 6 mo of age.
Fig. 6. Islet size and shape comparison of
islets isolated from LSD controls rats (A),
prediabetic (B), and diabetic UCD-T2DM
(C) rats. All animals are at 2.5 to 3 mo of age
and 3.5 wk of diabetes in the diabetic group.
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betic hypertriglyceridemia, increased visceral adiposity, and
ectopic TG deposition present at onset in these animals appear
more similar to what is observed clinically and support the
lipotoxicity hypothesis that lipid dysregulation and deposition
in muscle and liver contribute to insulin resistance in the
pathogenesis of T2DM (10).
While there are some existing nonmonogenic models of
diabetes such as the sand rat, which develops hyperglycemia
on a high-fat diet (48), and the high-fat diet-fed (HFD) strep-
tozotocin-treated rat (50), these models require dietary and/or
pharmaceutical manipulations whereas UCD-T2DM rats de-
velop T2DM when fed a standard chow diet. The need for such
additional treatments to produce diabetes in these models has
Fig. 7. Yield and size distribution of isolated islets (A; LSD: n  5, predia-
betic: n  5, and diabetic: n  3), islet volume (B: LSD: n  5, prediabetic:
n  5, and diabetic: n  3), and insulin content per islet volume (C: LSD: n 
5, prediabetic: n  5, and diabetic: n  3) in islets isolated from prediabetic
and diabetic UCD-T2DM rats and LSD control rats at 2.5 to 3 mo of age and
3.5 wk of diabetes in the diabetic group. Values are means 	 SE. One-way
ANOVA, *P 
 0.05, **P 
0.001 compared with prediabetic and diabetic
UCD-T2DM rats and ***P 
 0.001 compared with LSD and diabetic UCD-
T2DM rats by Bonferroni’s posttest.
Table 2. Monthly body weight and energy intake in lean
Sprague-Dawley and UCD-T2DM male rats
Age, mo
LSD UCD-T2DM
Body wt, g EI, kcal/day Body wt, g EI, kcal/day
1 97	2 48	1 118	3 50	4
2 260	4 72	2 365	9† 101	5*
3 323	6 68	2 510	13‡ 99	3†
4 359	7 65	1 586	16‡ 96	4†
5 388	7 65	3 618	16‡ 92	4*
6 410	7 66	1 629	16‡ 98	5*
7 431	9 68	1 627	18‡ 104	7†
8 446	9 69	1 613	17‡ 102	7†
9 454	8 64	4 595	17‡ 111	7‡
10 476	8 65	2 566	19‡ 123	8‡
Values are means	 SE. LSD: n 6; and UCD-T2DM: n 16. UCD-T2DM
animals from F9 and F10 generations. Two-way repeated measures ANOVA:
*P 
 0.05, †P 
 0.001, ‡P 
 0.0001, compared with lean Sprague-Dawley
(LSD) rats by Bonferroni’s posttest. EI, energy intake.
Fig. 8. Monthly body weight (A) and energy intake (B) before and after
diabetes onset in UCD-T2DM rats. Values are means	 SE. One-way repeated
measures ANOVA, **P
0.001 by Bonferroni’s posttest compared with value
at onset (n  16).
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several disadvantages. For example, both of these animal
models develop diabetes rapidly after the initiation of the
diabetogenic treatment which makes these models difficult for
use in the testing of preventative treatments. Furthermore,
despite their polygenic obesity, these animal models still
present etiologic disparities such as the need for pharmaceuti-
cally induced -cell destruction in the HFD streptozotocin-
treated rat and the extreme diet sensitivity expressed in the
sand rat, with younger animals developing hyperglycemia
within 14 days after initiation of a high-energy diet (23).
Inadequate insulin secretion to compensate for insulin resis-
tance followed by eventual -cell decompensation is a key
component of the pathogenesis of clinical T2DM (22) and is
clearly demonstrated in this model through longitudinal mea-
surements of glucose and insulin and through results from
IVGTTs, islet immunohistochemistry, and islet insulin content.
These results demonstrate a progressive loss of the ability to
maintain insulin production and glucose homeostasis, with
corresponding degenerative changes in islet morphology, and
decreased insulin staining and insulin content. The timing of
changes of insulin concentrations relative to diabetes onset
presented in Fig. 2 is similar to that seen in humans: insulin
levels rise significantly before diabetes onset, peak around the
time of onset, and decline as hyperglycemia becomes more
pronounced (21). Insulin immunostaining and measurement of
insulin content in isolated islets confirm the reduction in insulin
content with the progression of diabetes in these animals,
corresponding with what would be expected from the autoso-
mal recessive insulin promoter defect that is characteristic of
this model (15). Previous studies (32, 41) on islet histology of
lean ZDF rats do not demonstrate severe disruptions in islet
morphology or -cell mass. Our results thus confirm the
hypothesis that the pancreatic defect present in the ZDF lean
rat becomes pronounced only when the islets are challenged by
the presence of obesity-induced insulin resistance. Thus the
-cells of UCD-T2DM rats fail to adequately compensate for
obesity-induced insulin resistance. Furthermore, similar to
clinical T2DM, glucagon levels are elevated starting 4 mo after
onset, supporting a role for -cell dysregulation in the main-
tenance and progression of T2DM (7). Thus this model may
provide insight into the relative contributions of insulin resis-
tance and islet dysfunction in T2DM pathogenesis. Further
studies on what causes the observed -cell hypertrophy and
disruptions of islet morphology are needed.
There are a number of important and unique features that
support the utility of the UCD-T2DM rat as a model of T2DM.
With the preservation of leptin signaling, the animals remain
fertile. Preservation of fertility makes this model highly effi-
cient for T2DM studies in that all animals have the potential to
develop diabetes and all animals can be used for breeding. The
delayed onset of diabetes observed in UCD-T2DM rats allows
for testing of therapies aimed at diabetes prevention. The
UCD-T2DM rat manifests diabetes in both males and females,
providing a much needed model for examining gender-specific
characteristics of diabetes development. Specifically, female
UCD-T2DM rats demonstrate polygenic adult-onset obesity,
hyperglycemia, and albuminauria (data not shown). While the
present studies mainly focused on characterizing the males,
future studies will be carried out detailing the diabetic pathol-
ogy present in females. In particular, successful pregnancies
observed in females that developed diabetes while pregnant
suggest that UCD-T2DM rats may be useful as a model for
gestational diabetes, a disease for which a well-described
rodent model is lacking (3).
In addition to its utility as a model of diabetes etiology, these
animals appear to develop diabetic complications such as
diabetic nephropathy and lipid dysregulation. UCD-T2DM rats
demonstrate a 20% elevation in FFAs after onset, similar to
what is observed in clinical T2DM (4) and have moderately
elevated plasma TG concentrations before diabetes onset com-
pared with LSD rats. Interestingly, a similar moderate (38%)
elevation of plasma TG levels has been observed in measure-
ments made at 18, 12, and 6 mo before the diagnosis of
diabetes in 86 human subjects who developed type 2 diabetes
compared with 860 subjects who did not develop diabetes in
the West of Scotland Coronary Prevention Study (44). UCD-
T2DM rats exhibit diabetic renal complications as evidenced
by markedly elevated urinary albumin excretion. These results
suggest that the UCD-T2DM rat may serve as a useful model
for diabetic nephropathy.
Finally, the metabolic abnormalities present in UCD-T2DM
rats will provide productive grounds for future studies inves-
tigating the role of other hormones in the pathogenesis of
T2DM. For example, it is an ideal model to study the role of
and mechanisms by which decreased circulating adiponectin
concentrations are involved in the progression of T2DM.
Adiponectin is secreted by adipocytes in inverse proportion to
visceral adiposity and has insulin-sensitizing and anti-inflam-
matory effects (16, 19, 53). Obese humans with T2DM have
lower circulating adiponectin concentrations than nondiabetic
individuals (16). Similarly, circulating adiponectin concentra-
tions in male UCD-T2DM animals were 25% lower after
diabetes onset. This model may also provide insight into the
role of ghrelin in T2DM progression. The observed increase
Table 4. Visceral adipose weight and tissue triglyceride
content in LSD, OSD, and nondiabetic and recently diabetic
UCD-T2DM rats
Mesenteric M TG/g Tissue
Adipose Weight, g Gastrocnemius Liver
LSD 2.5	0.1 1.7	0.1 6.1	0.4
OSD 9.5	1.8‡ 4.4	0.8 16.0	3.2
Nondiabetic 7.8	0.7† 10.3	1.8 20.1	5.1*
Diabetic 9.4	0.9‡ 15.3	3.5† 32.4	3.4†
Values are means 	 SE. (LSD: n  6; obese Sprague Dawley (OSD): n 
6; nondiabetic: n  3; and diabetic: n  6]. One-way ANOVA: *P 
 0.05,
‡P 
 0.001, compared with LSD animals by Bonferroni’s posttest. One-way
ANOVA: †P 
 0.01, compared with LSD and animals by Bonferroni’s
posttest. TG, triglyceride.
Table 3. Urine volume, glucose, and UAE before and after
diabetes onset in UCD-T2DM rats
Months Before
or After Onset
Urine Volume,
ml/12 h
Urine Glucose,
mg/dl
UAE,
mg/day n
2 7	2 22	3 0.4	0.1 8
0 16	3 397	170† 0.7	0.1 8
3 31	8* 5,660	918† 3.2	1.0* 5
Values are means 	 SE. UAE, urinary albumin excretion. One-way repeat-
ed-measures ANOVA: *P 
 0.01, †P 
 0.001, compared with 2 mo before
onset by Bonferroni’s posttest.
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of circulating ghrelin after diabetes onset may appear to
contradict reports showing ghrelin to be lower in T2DM;
however, these studies were conducted in subjects with
treated T2DM and who are obese or overweight (43).
Furthermore, ghrelin has been shown to be decreased by
increased circulating levels of insulin (1, 14). This would
suggest that the loss in body weight and insulin production
observed after 4 mo of diabetes in this animal model may be
involved in the increase of ghrelin. Given that ghrelin has
been shown to inhibit insulin secretion (6), the increase of
ghrelin after diabetes onset suggests a potential for ghrelin
in diabetes progression.
Perspectives and Significance
In summary, the UCD-T2DM rat model exhibits a T2DM
etiology more similar to clinical T2DM in humans than other
rodent models such as the ZDF rat. These similarities include
obesity and insulin resistance of polygenic origin, later ages of
diabetes onset, development of diabetes in both male and
female animals that occurs on a standard rodent chow diet, and
importantly preserved fertility in both sexes (Table 5). Char-
acterization of the model indicates that the UCD-T2DM rat
will be a useful tool for investigating the pathophysiology,
prevention, and treatment of T2DM.
Fig. 9. A: longitudinal fasting plasma triglyceride (TG) and free fatty acids (FFA). TG: n  12 at 4 mo before onset, n  16 at all other time points; and FFA:
n  12 at 2 and 3 mo before onset, n  16 at all other time points. B: longitudinal fasting plasma adiponectin and leptin. Adiponectin: n  16 at all time points;
and leptin: n  13 at 3 mo before onset, n  16 at all other time points. C: longitudinal fasting plasma glucagon: n  13 at 4 mo after onset, n  16 at all other
time points. D: longitudinal fasting plasma ghrelin: n  12. Values are means 	 SE. One-way repeated measures ANOVA;, *P 
 0.05, ** P 
 0.001 compared
with value at onset; ***P 
 0.05 compared with value 1 mo before onset by Bonferroni’s posttest.
Table 5. Comparison of the UCD-T2DM rat with human T2DM and the ZDF rat model
Characteristic Human T2DM UCD-T2DM Rat ZDF Rat
Origin of obesity Polygenic Polygenic Monogenic leptin receptor mutation
Inherited -cell defect Likely Yes Yes
Age of T2DM onset Adolescent to adult Males: 183	10 days; females:
286	17 days
Males: 60–90 days
Gender-specific onset No Female onset approximately 3 mo
after males
Females develop diabetes only on a high-fat, high-
sugar diet
Fertility Preserved Preserved Infertile
Plasma TG elevation Usually moderate Moderate Severe
Liver and muscle TG accumulation Yes Yes Yes
ZDF, Zucker diabetic fatty.
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